The current study describes the synthesis and pharmacological evaluation of (E)-N-(3,7-dimethylocta-2,6-dienyl)-1,3-dimethyl-1H-pyrazol-5-amine (LQFM002), a compound originally designed through a molecular simplification strategy from 4-nerolidylcatechol. LQFM002 was evaluated for preservation of the PLA(2) enzyme inhibitory effects of the lead compound, 4-nerolidylcatechol, using
1,3-Oxazines and related compounds. II.1) Ring contraction reaction of 1, 3-oxazin-4-one derivatives into 1,2,4-triazoles and pyrazoles.
Yamamoto, et al.
Chemical & Pharmaceutical Bulletin, 26(6), 1825-1831 (1978)
The reaction of o?phthalaldchydic acid with 5?amino?1,3?dimethylpyrazole.
Swett LR and Aynilian GH.
Journal of Heterocyclic Chemistry, 12(6), 1135-1136 (1975)
The cyclocondensation of 5?amino?1,3?dimethylpyrazole with ethyl acetoacetate. Synthesis of isomeric pyrazolopyridones.
Ratajczyk JD and Swett LR.
Journal of Heterocyclic Chemistry, 12(3), 517-522 (1975)
Chemical & pharmaceutical bulletin, 52(9), 1098-1104 (2004-09-02)
A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.